The present invention relates to a novel medical use of compounds with
CB.sub.1-receptor activity selected from the group of
4,5-dihydro-1H-pyrazole derivatives, 1H-Imidazole derivatives, thiazole
derivatives and/or 1H-1,2,4-triazole-3-carboxamide derivatives, as each
defined in the specification, or of a prodrug thereof, a tautomer thereof
or a salt thereof, in the manufacture of medicaments for the treatment
and/or prophylaxis of CB.sub.1 receptor related diseases in juvenile
patients and/or for the treatment and/or prophylaxis of drug induced
obesity in juvenile, as well as in adolescent, patients. Furthermore, the
invention pertains to the use of said compounds with CB.sub.1-receptor
activity in combination with lipase inhibitors. Said compounds are
particularly suitable in combination with lipase inhibitors in the
manufacture of medicaments for the treatment and/or prophylaxis of
obesity in adolescent or in juvenile patients and/or for the treatment
and/or prophylaxis of drug induced obesity in juvenile as well as in
adolescent patients. Preferred lipase inhibitors are orlistat,
panclicins, ATL-962 and/or lipstatin.
